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The amplified Chlamydia trachomatis test (AMP-CT; Gen-Probe), a new diagnostic test for the detection of
Chlamydia trachomatis, was evaluated with urine specimens from 1,000 patients visiting the outpatient depart-
ment for sexually transmitted diseases at the University Hospital Rotterdam, Rotterdam, The Netherlands, by
comparing the results to those of cell culture. From February 1996 to July 1996, urine samples for the AMP-CT
test and urethral swabs for cell culture were collected from 544 men, while cervical swabs from 456 women were
also taken for cell culture. Positive test results were obtained for 130 (13%) of the patients. AMP-CT test and
cell culture results were discordant for 70 (7%) specimens. Analysis of the samples with discordant results was
performed by an in-house PCR. After resolution of the discordant results, the sensitivity, specificity, and
positive and negative predictive values of the AMP-CT test were 84.3, 98.8, 89.6, and 98%, respectively, for
samples from females and 100, 99.2, 93.1, and 100%, respectively, for samples from males, while for cell culture
these values were 72.5, 99.2, 92.5, and 98%, respectively, for samples from females and 57.4, 99.0, 86.1, and
95.4%, respectively, for samples from males. We conclude that the AMP-CT test is a fast and reliable test for
the detection of C. trachomatis in urine specimens from females and, in particular, males.
Infection with Chlamydia trachomatis is one of the most
important sexually transmitted diseases and has potentially
serious sequelae (9). C. trachomatis can cause infections of the
cervix, urethra, and upper genital tract in women, infections of
the urethra and epididymis in men, and conjunctivitis and
pneumonia in newborns (23). The most sensitive method for
the diagnosis of a genital C. trachomatis infection was, until
recently, based on culture of the microorganism on HeLa 229
or McCoy cells, which requires extensive laboratory facilities.
In addition, circumstances with regard to transport and storage
of the sample may influence the reliability of the cell culture
result considerably (17). A second major disadvantage is that it
takes several days before the test result is known. These dis-
advantages of the cell culture method have led to the search for
alternative techniques for the detection of C. trachomatis.
Apart from the development of antigen detection techniques,
such as direct fluorescent-antibody tests and enzyme immuno-
assays (3, 11, 21, 22), nucleic acid detection techniques have
been developed (7, 16, 18). These nucleic acid amplification
tests have generally been more sensitive than traditional tests
for the detection of C. trachomatis. The disadvantage of all
these tests still remained that the majority of assays had to be
performed with samples obtained from cervical or urethral
smears. A sensitive, reliable, and inexpensive assay for the
detection of C. trachomatis in specimens that can be easily
collected was urgently needed. Two such assays have been
marketed recently: the urine LCx assay from Abbott Labora-
tories based on the ligase chain reaction (LCR) (10) and the
AMPLICOR assay from Roche based on PCR (13). These
assays are based on the detection and amplification of C. tra-
chomatis DNA in urine and have proved to be reliable and
reproducible (4–6, 10, 13). A disadvantage of both of these
assays, however, is the need for thermocycling and, because
both assays are based on DNA amplification, the need for
stringent measures to prevent contamination. In this study, we
evaluated a new test, the Amplified Chlamydia trachomatis
(AMP-CT) test from Gen-Probe. This new test is based on
amplification of rRNA, which has several potential advantages.
Since the breakdown of one cell will result in the release of up
to 10,000 copies of rRNA, giving a head start in the amplifi-
cation process, the amplification time is short (2 h or less).
Detection uses the hybridization protection assay with acri-
dinium ester-labeled DNA probes which are specific for the
target organism (1, 2). The results of the AMP-CT test were
compared with the results of cell culture. An in-house PCR
technique was used for analysis of samples with discordant
results (12).
MATERIALS AND METHODS
Patient population and specimen handling. Specimens were collected from
544 men and 456 women visiting the outpatient department for sexually trans-
mitted diseases at the University Hospital of Rotterdam, Rotterdam, The Neth-
erlands, from February 1996 to July 1996. Samples were collected in a block
design, with 250 samples in each block, in the following order for females: block
one, cervical swab (CS), urethral swab (US), and first-void urine (FVU); block
two, FVU, CS, and US; block three, CS, US, and FVU; block four, FVU, CS, and
US. For males the order of collection was US and FVU over all blocks. The
chlamydial culture samples were collected with ENT Dacron swabs (Medical
Wire, Corsham, United Kingdom) and were placed in 1 ml of 0.2 M sucrose
phosphate buffer and stored at 4°C or, when not tested within 24 h after collec-
tion, at 270°C. Four Eppendorf tubes were filled with 1.5 ml of FVU for the
AMP-CT test and one tube was filled with 3 ml of FVU for the in-house PCR by
using aerosol-resistant tips (Molecular Bio-Products Inc., San Diego, Calif.).
This latter tube was stored at 220°C until processing. Of the four 1.5-ml tubes,
three were stored at 270°C for later reference and one was stored at 4°C until
processing, within 7 days.
Cell culture. Chlamydial culture was performed with cycloheximide-treated
McCoy cells in microtiter plates and has been described previously (14, 15, 24).
Briefly, two wells per plate were each inoculated with 0.2 ml of a patient sample.
After centrifugation at 1,400 3 g, for 60 min, the supernatant was replaced with
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0.1 ml of complete growth medium (Eagle minimal essential medium with Glu-
tamax [Flow Laboratories Inc., Paisley, Scotland]) containing 10% fetal calf
serum (Flow), 1% vitamins (Flow), 20 mg of gentamicin per liter, 5 mg of
amphotericin B per liter, 25 mg of vancomycin per liter, 4.5 g of glucose per liter,
and 1 mg of cycloheximide (pH 7.5; Sigma Chemical Co., St. Louis, Mo.) per
liter. The plates were incubated at 37°C in 5% CO2 for 48 h. Thereafter, the
monolayers were fixed with ethanol (96%) for 10 min and stained with a fluo-
rescent monoclonal antibody (Microtrak; Syva Co., Palo Alto, Calif.) specific for
C. trachomatis and examined for inclusions. Culture results were scored as
follows: 0, no inclusions per two wells; 1, 1 to 5 inclusions per two wells; 2, 6 to
20 inclusions per two wells; and 3, .20 inclusions per two wells.
AMP-CT test. The whole AMP-CT test procedure was carried out according
to the instructions of the manufacturer. The urine samples were incubated for 10
min at 37°C. After centrifuging the specimens at 8,000 3 g for 5 min, the
supernatant was decanted. The pellet was resuspended in 200 ml of specimen
diluent buffer, and 25 ml of amplification reagent was added to the propylene
reaction tubes. After adding 200 ml of oil reagent to the reaction tube, 50 ml of
processed specimen was pipetted under the oil reagent. The tubes were incu-
bated for 10 min at 95°C in a heating block (Diagnostics Grifols S.A., Barcelona,
Spain). After cooling down in a heating block at 42°C for 5 min, 25 ml of enzyme
reagent was added. After incubation for 1 h at 42°C in the same heating block,
20 ml of termination reagent was added and the mixture was incubated for 10 min
at 42°C in the heating block. After the addition of 100 ml of probe reagent, the
tubes were briefly vortexed and incubated for 15 min at 60°C in a water bath.
After adding 300 ml of selection reagent, the tubes were incubated for 10 min at
60°C in the water bath and were cooled down for 10 min at room temperature.
The hybridization protection assay with acridinium-ester-labeled DNA probes
(2) which are specific for the target organism was used for detection. Positive and
negative controls were included in every run.
PCR. (i) Urine specimens. The urine specimens were thawed at room tem-
perature and vortexed, and 1.5 ml was transferred to a clean tube and incubated
for 15 min at 37°C. The specimens were then centrifuged at 14,000 3 g for 30 min
at 37°C. The supernatant was removed and the pellet was treated with 80 ml of
lysis buffer (50 mM Tris-HCl [pH 7.5], 1% Triton X-100, 1 mM EDTA, 250 mg
of proteinase K per ml). After incubation at 37°C for 1 h, the DNA in the lysates
was extracted and purified with 4 M guanidine isothiocyanate and Celite by the
method of Boom et al. (8). At the final step the DNA was eluted in 100 ml of 10
mM Tris-HCl (pH 8.0).
(ii) Cervical and urethral swabs. A 400-ml sample of specimen was centrifuged
at 14,000 3 g for 30 min, and the pellet was treated with 40 ml of lysis buffer (50
mM Tris-HCl [pH 7.5], 1% Triton X-100, 1 mM EDTA, 250 mg of proteinase K
per ml). After incubation at 37°C for 1 h, the lysates were boiled for 10 min and
centrifuged briefly. From each lysate, 8 ml was added to 92 ml of the PCR
mixture.
Primers and PCR protocol. PCR was performed in a 100-ml volume under
standard conditions with 10 ml of DNA sample. The following primer set, gen-
erating a 517-bp fragment, was used: T1, GGACAAATCGTATCTCGG; T2,
GAAACCAACTCTACGCTG. PCR was performed in 100 ml of PCR solution
containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 200 mM
(each) deoxynucleoside triphosphate, 50 pmol of each primer, 0.1 mg of gelatin
per ml, 0.2 U of Taq DNA polymerase (Sphaero-Q, Leiden, The Netherlands),
and 10 ml of sample. The reaction mixture was overlaid with 100 ml of mineral oil
(Sigma) to prevent evaporation and was preincubated for 5 min at 94°C for DNA
denaturation. Thirty-five cycles of amplification were performed with a PCR
processor (Biomed GmbH, Theres, Germany). Each cycle consisted of a dena-
turation step at 94°C for 1 min, a primer annealing step at 55°C for 1 min, and
a chain elongation step at 74°C for 2 min. After 35 cycles, a temperature delay
step of 5 min at 74°C completed the elongation. A 40-ml volume of the amplified
PCR product was analyzed by agarose (1.5%; wt/vol) gel electrophoresis.
Southern blot analysis of PCR products. DNA was transferred from agarose
to Hybond plus nylon filters (Amersham International, plc, Amersham, United
Kingdom) by electrophoretic transfer. The PCR products were analyzed with a
C. trachomatis-specific probe (CGCAGCGCTAGAGGCCGGTCTATTTATGA
T).
Analysis of results. Analysis of samples with discordant results was performed
as follows. A result was considered to be true positive when cell culture results
were comparable to the AMP-CT test results. The results for all samples with
discrepant results were confirmed by using the in-house PCR. The in-house PCR
was performed with FVU, US, and CS, if applicable. A cell-culture-negative and
AMP-CT test-positive result was considered to be true positive if the PCR with
FVU was positive. If the PCR result was negative, the AMP-CT test result was
considered to be false positive. A cell culture-positive and AMP-CT test-negative
result was considered to be false negative if the result with FVU PCR was
positive. If the PCR result with FVU was negative and the US and/or CS
specimen was PCR positive, the AMP-CT test was considered to be false nega-
tive due to sample-to-sample variation. DNA was isolated from cells in the
inoculated cell culture monolayers, which was followed by PCR if the FVU and
US (and CS, if applicable) remained negative by PCR. The cell culture result was
considered true positive if the inoculated monolayer was PCR positive.
The SAS statistical program, version 6.08 (20), was used for analysis of the
results. The Fisher test was used for statistical evaluation. Statistical significance
was accepted at P # 0.05 (two-tailed).
RESULTS
The results of cell culture compared to those of the AMP-
CT test are presented in Table 1. The prevalence of chlamydial
infection for the entire group (n 5 1,000), as measured by a
positive culture result, was 7.7%. For males (n 5 544) and
females (n 5 456) the prevalences were 6.8 and 8.8%, respec-
tively.
In a comparison of the AMP-CT test results with those of
cell culture, the sensitivity, specificity, and positive and nega-
tive predictive values were 77.9, 94.2, 46.9, and 98.1%, respec-
tively.
AMP-CT test and cell culture results were discordant for 70
(7%) of the samples. Table 2 presents the results of the anal-
ysis of samples with discordant results. In total, results for eight
samples were discordant due to sample-to-sample variation.
More than half of the samples with discordant results (37 of
70), were considered to be false negative by culture. Of the
eight samples that were false negative by the AMP-CT test, all
were from females.
After resolution of discordant results by PCR, the sensitivity,
specificity, and predictive values were determined for both the
AMP-CT test and cell culture (Table 3). The sensitivity of the
AMP-CT test appears to be much higher than that of cell
culture (92.4 versus 64.8%). The specificities of both tech-
niques were quite similar. To determine whether the sensitiv-
ities of the assays were related to the order of sampling, the
results were analyzed for samples within each block. There
were no significant differences in sensitivity between the blocks
for either culture or the AMP-CT test (P . 0.2) (data not
shown). To determine whether the sensitivity of the AMP-CT
test was related to the load of C. trachomatis in the samples,
the sensitivity was compared for samples for which different
numbers of inclusions were found in cell culture. There was no
significant difference in the sensitivity of the AMP-CT test
between samples with scores of 1 and those with scores of 2 or
3 (P . 0.2).
TABLE 1. AMP-CT test and cell culture results for detection
of C. trachomatis in males and females
Gender and cell
culture result
No. of subjects with the
following AMP-CT
test result:
Positive Negative
Males (n 5 544)
Positive 31 6
Negative 33 474
Females (n 5 456)a
Positive urethra and positive cervix 12 3
Positive urethra and negative cervix 1 1
Negative urethra and positive cervix 16 7
Negative urethra and negative cervix 20 396
Positive urethra or positive cervix 29 11
Overall (n 5 1,000)
Positiveb 60 17
Negative 53 870
a One female had no cervix.
b Positive culture result for either cervical or urethral sample.
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DISCUSSION
In this study, we evaluated the value of a new technique, the
AMP-CT test, for detecting C. trachomatis in urine samples.
One of the remarkable findings in this study was the number of
false-negative culture results. More than half of the samples
with discordant results had false-negative culture results.
Other amplification techniques, such as the commercially
available AMPLICOR PCR and the LCx, have provided sim-
ilar results (4, 5, 10, 13). There are several explanations for
this. Theoretically, one inclusion would be enough to show a
positive result in a PCR-based test, while culture has been
shown to need multiple elementary bodies to be positive. An-
other argument which is often used is that culture techniques
need viable elementary bodies to become positive, while am-
plification techniques only show the presence of DNA (or
RNA). Patients who have been successfully treated with anti-
chlamydial agents can remain positive for some time. Since the
AMP-CT test is based on RNA amplification, in contrast to the
AMPLICOR and the LCx, it could be expected that this issue
is of less importance for this technique. RNA is much less
stable than DNA in the environment and is degraded quickly
by naturally occurring RNases (19). On the other hand, the
AMP-CT test is based on amplification of rRNA, making use
of the thousands of copies of the sequence to be detected,
while only 10 copies per inclusion are available for the DNA
amplification techniques. Which of the two forgoing mecha-
nisms is going to prevail remains to be investigated. Alterna-
tively, it has been shown that C. trachomatis can persist in
mononuclear phagocytes, which can be responsible for the
prolonged positive amplification reaction. It is then the lon-
gevity of the phagocytes rather than the persistence of DNA or
RNA in situ which determines the duration of positivity.
Therefore, although the amplification techniques are prob-
ably more sensitive overall than cell culture, the sensitivity is
still not 100%. After discrepancy analysis, eight samples yield-
ed false-negative AMP-CT test results, and these were all from
females. One explanation may be that inhibitory substances
were present in the sample. Inhibitory substances have been
shown to influence PCR-based results considerably (25). This
finding warrants further study.
In this study, we chose to analyze the results after analysis of
samples with discordant results but not including those sam-
ples with discordant results due to sample-to-sample variation
(a total of eight samples). This could be debated, since it could
be argued that the purpose of testing is to find whether a
person is infected, irrespective of the method used. In that case
the figures in this study would have provided slightly different
results. Seven of the eight sample-to-sample variations oc-
curred with samples from the AMP-CT test-positive and cul-
ture-negative group, mostly with samples from males (Table
2). The sensitivity of the AMP-CT test would therefore in-
crease. Among the samples from the AMP-CT test-negative
and culture-positive group, results for only one of the samples
varied among the tests. The sensitivity for samples from males
would be slightly lower if this sample is taken into consider-
ation as a false-negative AMP-CT test result and would de-
crease from 100 to 98.4%.
The overall prevalence found by cell culture was somewhat
lower than that found in earlier studies in our hospital. In a
study performed in 1991, we found prevalences of 8.7 and
13.5% for females and males, respectively, compared to preva-
lences of 8.8 and 6.8%, respectively, in this study. It appears
that the lower prevalence is due to a shift in the prevalence in
males only. Although this figure increases after resolution of
the results for samples with discordant results between the
tests, we have no explanation for this. It seems, however, that
the prevalence of Chlamydia in the male population is decreas-
ing. This may be explained by the difference in clinical symp-
toms between males and females. Most male C. trachomatis
infections are symptomatic, while 75% of the female C. trach-
omatis infections remain asymptomatic (9). Successful preven-
tion strategies and the availability of C. trachomatis diagnostic
tools may also contribute to this decline.
Both PCR with the original sample and PCR with material
obtained from the culture wells were negative for eight sub-
jects, whose samples were initially culture positive and
AMP-CT negative, yielding a specificity of less than 100% for
TABLE 2. Number of patients whose samples had shown discrepant cell culture and AMP-CT test results and interpretation
after resolution by PCR analysis
Discordance PCR result No. of samples
Explanation
AMP-CT test result Culture result Urine CS/US Male Female
1 2 1 2 6 1 Sample-to-sample variability
1 1 22 9 False-negative culture
2 1 1 5 False-negative culture
2 2 4 5 False-positive AMP-CT test
2 1 2 1 1 0 Sample-to-sample variability
1 1 0 5 False-negative AMP-CT test
1 2 0 1 False-negative AMP-CT test
2 2 5 5 False-positive culture (n 5 8) or false-negative AMP-CT test (n 5 2)a
a These two samples (both from females) were PCR positive in the culture wells.
TABLE 3. Sensitivity, specificity, and positive and negative
predictive values for the AMP-CT test and cell culture
after resolution of discordant results
Group and
test
Sensitivity
(%)
Specificity
(%)
Predictive value (%)
Positive Negative
Females
AMP-CT 84.3 98.8 89.6 98.0
Cell culture 72.5 99.2 92.5 96.6
Males
AMP-CT 100 99.2 93.1 100
Cell culture 57.4 99.0 86.1 95.4
Overall
AMP-CT 92.4 99.0 91.5 99.1
Cell culture 64.8 99.1 89.5 96.0
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cell culture. There are several explanations for this. One pos-
sibility would be that only one C. trachomatis elementary body
was present in the whole sample. However, in that case the
PCR with material from the culture wells should have been
positive for at least some of the samples and is further mainly
of theoretical interest. A second possibility would be that there
is aspecific binding of the C. trachomatis-specific monoclonal
antibodies or other fluorescent artifacts. We are evaluating the
sensitivity and specificity of several other assays, including the
PACE-2 assay (Gen-Probe), for the detection of C. trachoma-
tis, and although more assays are used and thus the overall
sensitivity increases, preliminary results indicate there are still
some false-positive culture results, probably on the basis of the
last of the two foregoing explanations (data not shown).
We conclude that the AMP-CT test is a fast and reliable test
for the detection of C. trachomatis in urine specimens from
females and, in particular, males.
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